Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

Eribulin mesylate has efficacy in patients who have received ≥2 prior chemotherapies for metastatic breast cancer (MBC) including an anthracycline and taxane. Phase 2 trials showed clinical activity and acceptable tolerability of first-line eribulin (HER2− MBC; Study 206) and eribulin plus trastuzum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Springerplus
Main Authors: O’Shaughnessy, Joyce, McIntyre, Kristi, Schwartzberg, Lee, Wilks, Sharon, Puhalla, Shannon, Berrak, Erhan, Song, James, Vahdat, Linda
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4577494/
https://ncbi.nlm.nih.gov/pubmed/26413438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-1322-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados